Achyut Healthcare Ltd (ACHYUT) — shareholding pattern, promoter holding, financials and share price
About Achyut Healthcare Ltd (ACHYUT)
Achyut Healthcare Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ACHYUT and on the BSE under scrip code 543499. Its ISIN is INE0K1401020.
Incorporated in 1996, Achyut Healthcare Ltd is a pharmaceutical trading company dealing in API, Pharmaceutical products, medical devices, etc. [1]
Achyut Healthcare Limited is primarily involved in trading pharmaceutical products such as drugs, vitamins, and medical equipment, catering to both domestic and international markets.
Despite its focus on pharmaceutical trading, Achyut Healthcare has created a significant market presence in countries like UAE, Kenya, and Nigeria while operating across India.
Listed peers in Pharmaceuticals: Brooks Laboratories Ltd, Gujarat Inject (Kerala) Ltd, Accretion Nutraveda Ltd, Oxygenta Pharmaceutical Ltd, Sanjivani Paranteral Ltd, Accretion Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹8.2 a share on 10 Jul 2026, Achyut Healthcare Ltd (ACHYUT) was valued at a price-to-earnings ratio of 659.71x against an industry P/E of 36.41x and a price-to-book of 6.32x on a book value of ₹1.3 per share as of Mar 2025. Solomo computes return on equity of 0.96% and return on capital employed of 1.34% from filed results. Earnings ratios use standalone results for the twelve months Mar 2025 to Mar 2026.
- P/E
- 659.71x
- Industry P/E
- 36.41x
- P/B
- 6.32x
- EPS (TTM)
- ₹0.01
- Book value / share
- ₹1.3
- ROE
- 0.96%
- ROCE
- 1.34%
- ROA
- 0.92%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- 4.83%
- 52-week range
- ₹7.81 – ₹8.55
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Achyut Healthcare Ltd (ACHYUT) reported revenue of ₹11.59 crore, net profit of ₹0.32 crore and earnings per share of ₹0.01. That compares with revenue of ₹3.05 crore and net profit of ₹0.55 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹4.39 crore and net profit ₹0.06 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 4.05 | 2.7 | 6.14 | 3.05 | 11.59 |
| Net profit (₹ cr) | 0.04 | 0.23 | 0.5 | 0.55 | 0.32 |
| EPS (₹) | 0 | 0.01 | 0.02 | 0.02 | 0.01 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 55.60% | -9.04% | -50.33% |
| Profit growth | 108.20% | 138.64% | 10.00% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 47.4% of Achyut Healthcare Ltd (ACHYUT) (unchanged from the previous quarter), foreign institutional investors (FII) hold 5.13%. Market capitalisation was ₹198 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2022.
Largest disclosed public shareholders in Jun 2026: DHARAM PRAKASH TRIPATHI 15.87%, ISEM MEHMET 5.13%, RUCHI SIMLOTE 2.72%, HUF 2.17%, PRADEEP KUMAR SINGH 1.21%, KRUPA KISHANBHAI RACHCHHA 1.2%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 47.4% | - | 5.13% | - | 52.6% |
| Mar 2026 | 47.4% | - | 5.13% | - | 52.6% |
| Dec 2025 | 47.4% | - | 5.13% | - | 52.6% |
| Sep 2025 | 47.07% | - | 5.26% | - | 52.93% |
| Jun 2025 | 46.38% | - | 6.14% | - | 53.62% |
| Mar 2025 | 46.11% | - | 8.14% | - | 53.89% |
| Sep 2024 | 46.11% | - | 6.14% | - | 53.89% |
| Mar 2024 | 44.8% | - | - | - | 55.2% |